Networks, Consortia & Programs

This program supports research projects focused on discovery of novel immunoprevention pathways and immune targets.

Research Centers develop and conduct early phase clinical trials to assess the preventive potential of agents and interventions of varying classes.

Advanced training for fellows provides a strong foundation in the field of cancer prevention and control to scientists and clinicians from varied health disciplines.

As a central component of the Cancer Moonshot^sm, the National Cancer Institute (NCI) is starting a new Cancer Screening Research Network (CSRN) in January 2024 that will conduct trials and studies to systematically evaluate promising and emerging technologies for the purpose of cancer screening.

A consortium of multi-disciplinary teams that is developing new methods for analyzing patient-reported outcomes in the setting of cancer clinical trials.

Research Units integrate imaging strategies with biomarkers to improve cancer screening, early detection of aggressive cancer, assessment of cancer risk, and diagnosis of early stage cancer.

This supports the discovery and development of novel natural products that are safe, non-toxic, and efficacious for cancer interception and prevention

Labs and centers bring together comprehensive infrastructure and resources critical to discovery, development and validation of biomarkers for cancer risk and early detection.

A partnership with academic and industrial laboratory teams developing noninvasive liquid biopsy techniques to detect early stage cancer from biomarkers in blood, urine and sputum.

NCI is creating a Lung Image Library for use by Artificial Intelligence researchers to improve lung cancer screening.

A public private partnership between several stakeholders to validate self-collection as a comparable (non-inferior) alternative to provider-collected sampling for HPV testing in cervical cancer screening.

A clinical trials network of cancer professionals brings research to diverse populations across the country in the communities where most patients live.

Research teams develop and test new molecular and imaging biomarkers to detect early stage pancreatic ductal adenocarcinoma and its precursor lesions.

The peer-reviewed research pipeline supports new prevention interventions and biomarkers headed toward clinical trials.

Clinical trials and grant-funded projects examine symptoms and morbidities related to cancer and its treatment, with a focus on interventions to improve quality of life.

Five Translational Research Centers conduct studies to improve surveillance of liver cancer in high-risk populations, increase detectability at early stages, and stratify at-risk patients.